UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 16, 2006
INGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Georgia 000-28704 88-0429044
------- ----------- ----------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification Number)
35193 Avenue "A", Suite-C, Yucaipa, California 92399
---------------------------------------------- -----
(Address of principal executive offices) (Zip Code)
(800) 259-9622
--------------
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
1.01 Entry into a Material Definitive Agreement
As of November 16, 2006, Ingen Technologies, Inc. has secured all the
signatures for the transfer of intellectual property rights for OxyView(TM).
Contracts titled "Technology And Patent Pending Purchase & Sale Agreement" have
been executed between Ingen Technologies, Inc. and the grantors, Richard
Campbell and Francis McDermott. All technology and rights to patents pending in
the United States, Japan, Peoples' Republic of China and the European
Communities are involved. Consideration for these agreements is the issuance of
common stock (Campbell), a common stock option (McDermott) and a royalty of 4%
of gross revenues (McDermott). In addition, the company and Mr. McDermott have
entered into an Addendum to Patent Rights Purchase & Sale Agreement. The
Addendum modifies the original Patent Rights Purchase and Sale Agreement by
changing the royalty provision from 4% of gross profits to 4% of gross revenues.
All of these agreements are included as exhibits hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: November 17, 2006 Ingen Technologies, Inc.
By: /s/ Scott R. Sand
-------------------------------------
Scott R. Sand,
Chief Executive Officer and Chairman
TABLE OF EXHIBITS
(All Exhibits have been properly signed by the parties.
Original agreements are filed in our offices)
EXHIBIT NO. DESCRIPTION
99.1 Technology And Patent Pending Purchase and Sale Agreement
between Ingen Technologies, Inc. and Richard Campbell,
grantor, dated November 7, 2006.*
99.2 Technology And Patent Pending Purchase and Sale Agreement
between Ingen Technologies, Inc. and Francis McDermott,
grantor, dated November 7, 2006.*
99.3 Addendum to Patent Rights Purchase and Sale Agreement between
Ingen Technologies, Inc. and Francis McDermott, grantor, dated
November 7, 2006.*
99.4 Patent Rights Purchase and Sale Agreement between Ingen
Technologies, Inc. and Francis McDermott, grantor, dated July
11, 2005 incorporated by this reference as filed in the
registrant's Form 10-KSB for the fiscal year ending May 31,
2005.
* filed herewith